CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Biological sample collectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug718 Data Collection: Clinical Care Assessments Wiki 0.71
drug2155 SF12, EQ-5D-5L and work status standardized quantitative assessments Wiki 0.71
drug748 Dexamethasone Wiki 0.41

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002647 Chilblains NIH 0.41
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients With COVID-19 (DAIT-COVID-19-002)

This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify immunophenotypic and genomic features of COVID-19 -related susceptibility and/or progression. The aim: for the results obtained from this study to assist in generating hypotheses for effective host-directed therapeutic interventions, to help to prioritize proposals for such interventions, and/or optimize timing for administration of host-response directed therapeutics.

NCT04378777 Coronavirus Disease 2019 (COVID-19) SARS-CoV-2 Procedure: Biological sample collection Procedure: Data Collection: Clinical Care Assessments
MeSH:Coronavirus Infections

Primary Outcomes

Description: The incidence of mortality in the first 28 days.

Measure: Mortality Rate Among COVID-19 Patients

Time: Day 1 to Day 28

Description: As a measure of disease acuity and severity.

Measure: Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 28

Time: Day 1 to Day 28

Description: As a measure of disease acuity and severity.

Measure: Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection Over Time to Day 28

Time: Day 1 to Day 28

Description: Ribonucleic acid (RNA) from the nasal swab will be used to assess SARS-CoV-2 viral load.

Measure: Mechanistic: Longitudinal Assessment of Viral Load by Semi-Quantitative Polymerase Chain Reaction (PCR) Over Time to Day 28

Time: Day 1 to Day 28

Description: Focus on the immune response to SARS-CoV-2, seroconversion and immunoglobulin and transitions. Antibody isotypes present in a patient specimen(s) provide information about the timing of initial exposure and may provide insight on the progression of the disease and prognosis.

Measure: Mechanistic: Antibody Isotype/Subclass Classification and Functionality Over Time through Day 28 and at follow-up through month 12

Time: Up to 12 Months

Description: Collected as part of clinical care.

Measure: Mechanistic: Longitudinal Assessment of Inflammatory Mediators as Collected Over Time to Day 28

Time: Day 1 to Day 28

Description: Collected as part of clinical care.

Measure: Mechanistic: Longitudinal Assessment of Markers of Myocardial Injury Over Time to Day 28

Time: Day 1 to Day 28

Secondary Outcomes

Description: A measure of disease morbidity.

Measure: Duration of Mechanical Ventilation in Patients with COVID-19 Over Time to Day 28

Time: Day 1 to Day 28

Description: A measure of disease morbidity.

Measure: Proportion of Patients with COVID-19 with Requirement for New (Or Increased from Baseline if on Home Oxygen) Supplemental Oxygen Over Time to Day 28

Time: Day 1 to Day 28

Description: A measure of disease morbidity.

Measure: Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients with COVID-19 Over Time to Day 28

Time: Day 1 to Day 28

Description: Method of immune profiling and quantitating the response to COVID-19 over time.

Measure: Mechanistic: Immune Cell Frequencies and Activation Status (CyTOF) in Blood and Endotracheal Aspirate over time Through Day 28 and In blood at Select Study Visits Through Month 12

Time: Up to 12 Months

Description: To identify and quantitate differences in immune response associated with disease outcome.

Measure: Mechanistic: Gene Expression (Transcriptomics) in Blood

Time: Up to 12 Months

Description: To identify and quantitate differences in immune response associated with disease outcome.

Measure: Mechanistic: Gene Expression (Transcriptomics) in Respiratory Epithelium

Time: Up to 12 Months

Description: To identify and quantitate differences in immune response associated with disease outcome.

Measure: Mechanistic: Gene Expression (Transcriptomics) in Plasma Protein

Time: Up to 12 Months

Description: To identify and quantitate differences in immune response associated with disease outcome.

Measure: Mechanistic: Gene expression (Transcriptomics) in Metabolic Profiling

Time: Up to 12 Months

Description: Circulating immune biomarkers will be explored by use of the OLINK® (name of brand), a multiplex protein biomarker discovery panel.

Measure: Mechanistic: Circulating Immune Mediators Assessed by OLINK Methodology

Time: Up to 12 Months

2 Chilblains, COVID-19 and Lockdown: Epidemiologic Study

Chilblains (inflammatory lesion of the feet or hands) have been reported with an unusual frequency during the confinement period, most commonly in children, teenagers and young adults. The aim of the ECCES study is to find out whether these manifestations of chilblains can be linked to the SARS-CoV-2 coronavirus. For this, an epidemiologic study will compare two types of family (or more precisely people who were confined together in March-April-May): - "case family" in which at least one of the members had chilblains - "comparator family" in which none of the members had chilblains Environment (home lockdown) of the two types of family will be analyzed. Each member of the "family" will be suggested doing a serological test.

NCT04455308 Chilblains COVID-19 Diagnostic Test: Biological sample collection
MeSH:Chilblains

Primary Outcomes

Measure: Level of viral exposure in "case family" compared to "comparator family"

Time: Through study completion, an average of 3 months

Secondary Outcomes

Measure: Comparison of seropositivity rates in subjects with chilblains and their age-matched controls

Time: Through study completion, an average of 3 months

Measure: Comparison of SARS-CoV-2 seropositivity rates among members of case (subject with chilblains) and control (subject without chilblains) outbreaks

Time: Through study completion, an average of 3 months

Measure: Antibody avidity and differentiated IgG and IgM assay by subject in the homes

Time: Through study completion, an average of 3 months

No related HPO nodes (Using clinical trials)